Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Poor and pregnant: perinatal ganja use in rural Jamaica.

Authors: Melanie C. Dreher
Advances in Alcohol & Substance Abuse, 1989

This paper reports the ethnographic findings from a study of cannabis use by pregnant women in rural Jamaica. The perceived functions of ganja in reducing the physiological symptoms of pregnancy and associated psychological stress are described in relation to the sociocultural…

Pharmacokinetics of cannabidiol in dogs.

Authors: E Samara, M Bialer, R Mechoulam
Drug Metabolism and Disposition: The Biological Fate of Chemicals, May/June 1988

Cannabidiol (CBD) is one of the major nonpsychoactive cannabinoids produced by Cannabis sativa L. Recent studies have shown that CBD has a high protective index, comparable to that of phenobarbital and phenytoin. Because CBD has been reported to possess both anticonvulsant and…

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.

Authors: A. W. Zuardi, I. Shirakawa, E. Finkelfarb, I. G. Karniol
Psychopharmacology, DATE

The object of the experiment was to verify whether cannabidiol (CBD) reduces the anxiety provoked by delta 9-THC in normal volunteers, and whether this effect occurs by a general block of the action of delta 9-THC or by a specific anxiolytic effect. Appropriate measurements an…

Hypnotic and antiepileptic effects of cannabidiol.

Authors: Elisaldo A. Carlini, Jomar M. Cunha
The Journal of Clinical Pharmacology, August-September 1981

Clinical trials with cannabidiol (CBD) in healthy volunteers, isomniacs, and epileptic patients conducted in the authors’ laboratory from 1972 up to the present are reviewed. Acute doses of cannabidiol ranging from 10 to 600 mg and chronic administration of 10 mg for 20 days o…

Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

Authors: Jomar M. Cunha, E.A. Carlini, Aparecido E. Pereira, Oswaldo L. Ramos, Camilo Pimentel, et al
Pharmacology, 1980

In phase 1 of the study, 3 mg/kg daily of cannabidiol (CBD) was given for 30 days to 8 health human volunteers. Another 8 volunteers received the same number of identical capsules containing glucose as placebo in a double-blind setting. Neurological and physical examinations…

Pharmacokinetics of delta9-tetrahydrocannabinol in dogs.

Authors: Edward R. Garrett, Edward R. Garrett, C. Anthony Hunt
Journal of Pharmaceutical Sciences, March 1977

The pharmacokinetics of intravenously administered 14C-delta9-tetrahydrocannabinol and derived radiolabeled metabolites were studied in three dogs at two doses each at 0.1 or 0.5 and 2.0 mg/kg. Two dogs were biliary cannulated; total bile was collected in one and sampled in th…

Antitussive activity of some naturally occurring cannabinoids in anesthetized cats.

Authors: Robert Gordon, Robert J.Gordon, R.Duane Sofia
European Journal of Pharmacology, February 1976

Experimental cough was elicited in pentobarbital-anesthetized cats by either electrical stimulation of the superior laryngeal nerve or by mechanical stimulation of the tracheal mucosa. Intravenous administration of delta9-tetrahydrocannabinol (THC) effectively reduced the ampl…

Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats.

Authors: Juhn A. Wada, Akira Wake, Mitsumoto Sato, Michael E. Corcoran
Epilepsia, September 1975

Acute administration of delta8-tetrahydrocannabinol (delta8-THC) or delta9-THC failed to affect partially developed or fully developed kindled amygdaloid seizures in cats. However, delta9-THC was quite effective in suppressing focal AD in the stimulated amygdala when administe…

Cardiovascular and respiratory effects of cannabis in cat and rat.

Authors: J. D. P. Graham, D. M. F. Li
British Journal of Pharmacology, September 1973

1. In anaesthetized rats, intravenous administration of cannabis extract (10 mg/kg), Delta(1)-tetrahydrocannabinol (THC) (0.5 mg/kg) and Delta(6)-THC (0.5 mg/kg) caused a reduction in systemic blood pressure, pulse rate and respiratory rate.2. Neither cannabinol (1 mg/kg, i.v…